Goserelin：天然的促性腺激素释放激素类似物，与 (D - His2)-Goserelin 结构相似，只是第二位氨基酸为 L - 组氨酸。 两者在作用机制和临床应用上有相似之处，但 (D - His2)-Goserelin 可能具有一些独特的优势，如更好的稳定性或更强的受体结合能力。

对比这些杂质与 Goserelin EP Impurity E 的结构和性质，可加深对该杂质的理解，以及对整个 GnRH 类似物杂质谱的认识。 6. 相关文献 由于公开资料有限，暂未检索到专门针对 Goserelin EP Impurity E 的相关文献。

TerSera Therapeutics LLC announced today that The National Comprehensive Cancer Network® (NCCN) Breast Cancer Panel included both goserelin 3.6 mg every 4 weeks and goserelin 10.8 mg every 12 weeks, ...

TerSera Therapeutics LLC announced that The National Comprehensive Cancer Network® Head and Neck Cancers Panel included a category 2B recommendation for goserelin as useful, in certain circumstances, ...

Abstract. The OPTION trial examined whether or not premenopausal women with early breast cancer receiving chemotherapy benefited from ovarian function protection with goserelin. This trial showed some ...

The GnRH agonist goserelin preserved fertility and improved pregnancy and survival in ER-positive breast cancer patients receiving chemotherapy in a study discussed by Dr Lidia Schapira.

Use of the gonadotropin-releasing hormone agonist, goserelin, protects against ovarian failure, according to a study.

THURSDAY, March 5, 2015 (HealthDay News) -- For patients with breast cancer, use of the gonadotropin-releasing hormone agonist, goserelin, protects against ovarian failure, according to a study ...

For patients with breast cancer, use of the gonadotropin-releasing hormone agonist, goserelin, protects against ovarian failure.

Goserelin, a gonadotropin-releasing hormone agonist, reduces ovarian failure and improves fertility in women treated with chemotherapy for breast cancer, according to results from the Prevention of ...